Policy Notices

• Policy Update - Results Information Reporting for Applicable Clinical Trials (ACTs)
  (NOT-OD-20-147)
  National Institutes of Health
  

• Upcoming Changes to the Notice of Award (NoA) Beginning October 1, 2020
  (NOT-OD-20-155)
  National Institutes of Health
  

General Notices

• NCCIH Policy Change to Budget Limit and Grant Durations for SBIR/STTR Phase I and Phase II Applications
  (NOT-AT-20-017)
  National Center for Complementary and Integrative Health
  

• Notice of information to PAR-18-746, " NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)"
  (NOT-DA-20-072)
  National Institute on Drug Abuse
  

• Notice of Pre-Application Information Webinar for RFA-DA-21-009, "Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents (R01 - Clinical Trial Optional)"
  (NOT-DA-20-078)
  National Institute on Drug Abuse
  

• Notice of Pre-Application Webinar for the Chronic Kidney Diseases of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium
  (NOT-DK-20-037)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Informational Webinar on the NIH Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Program Funding Opportunity Announcements (UE5 and K99/R00)
  (NOT-GM-20-048)
  National Institute of General Medical Sciences
  

• Solicitation of Nominations for the 2021 National Institute of Neurological Disorders and Stroke (NINDS) Landis Award for Outstanding Mentorship
  (NOT-NS-20-093)
  National Institute of Neurological Disorders and Stroke
  

• Accelerating Clinical Care and Research through the Use of the United States Core Data for Interoperability (USCDI)
  (NOT-OD-20-146)
  National Institutes of Health
  

• Findings of Research Misconduct
  (NOT-OD-20-154)
  National Institutes of Health
  

• Notice of Technical Assistance Webinars for Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) RFAs: RFA-RM-20-015, RFA-RM-20-016, RFA-RM-20-017, RFA-RM-20-018
  (NOT-RM-20-024)
  Office of Strategic Coordination (Common Fund)
  

• Request for Information (RFI):Advancing Biomarker Research and Implementation to Personalize Health Services Delivery for Tobacco Use Disorder
  (NOT-DA-20-073)
  National Institute on Drug Abuse
  

• Request for Information (RFI) on Clarification of Institutional Responsibilities Regarding Grant to Protocol Congruency
  (NOT-OD-20-153)
  National Institutes of Health
  

Notice of Changes to Funding Opportunities

• Notice to Extend the Expiration Date of PAR-18-189 Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
  (NOT-AG-20-045)
  National Institute on Aging
  

• Notice to Extend the Expiration Date of PAR-18-190 Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
  (NOT-AG-20-046)
  National Institute on Aging
  

• Notice of Termination: PAR-20-136 "Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)"
  (NOT-CA-20-083)
  National Cancer Institute
  

• Notice of Extension of the Expiration Date of PAR-18-654 "Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)"
  (NOT-CA-20-089)
  National Cancer Institute
  

• Notice of Extension of the Expiration Date of PAR-18-655 "Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
  (NOT-CA-20-090)
  National Cancer Institute
  

• Notice of Correction to Eligibility Information in PAR-20-278 "NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)"
  (NOT-CA-20-093)
  National Cancer Institute
  

• Notice of Change to Application Types Allowed in Funding Opportunity Announcement PAR-19-361 "Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)"
  (NOT-CA-20-094)
  National Cancer Institute
  

• Notice of Correction to PAR-20-225, "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)"
  (NOT-DA-20-075)
  National Institute on Drug Abuse
  

• Notice of Correction to PAR-19-223, "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)"
  (NOT-DA-20-076)
  National Institute on Drug Abuse
  

• Notice of NIDCR's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"
  (NOT-DE-20-030)
  National Institute of Dental and Craniofacial Research
  

• NHLBI Withdraws Participation in NOT-MD-20-022 "Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations"
  (NOT-HL-20-802)
  National Heart, Lung, and Blood Institute
  

• Notice of ORWH's and NICHD's Participation in PAR-20-179, "Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)"
  (NOT-OD-20-150)
  Office of Research on Women's Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of ORWH's and NICHD's Participation in PAR-20-180, "Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)"
  (NOT-OD-20-151)
  Office of Research on Women's Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for HEALthy Brain and Child Development Study
  (NOT-DA-20-069)
  National Institute on Drug Abuse
  

• Notice of Intent to Publish a Funding Opportunity Announcement for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Coordination and Evaluation Center (U54 Clinical Trial Not Allowed)
  (NOT-RM-20-022)
  Office of Strategic Coordination (Common Fund)
  

• Notice of Intent to Publish a Funding Opportunity Announcement for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Not Allowed)
  (NOT-RM-20-023)
  Office of Strategic Coordination (Common Fund)
  

Requests for Proposal

• Notice of Information: FNIH Cancer Steering Committee Project Concepts for Novel Biomarker Platforms in Understanding Tumor Heterogeneity
  (NOT-CA-20-092)
  National Cancer Institute
  

Funding Opportunities

• Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed)
  (PA-20-252)
  Office of Dietary Supplements
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): October 15, 2020, January 15, 2021, April 15, 2021, October 15, 2021, January 17, 2022, and April 15, 2022, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)
  (PAR-20-254)
  National Human Genome Research Institute
  National Cancer Institute
  National Eye Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): New Application Due Dates: October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Renewal, Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21) (Clinical Trial Optional)
  (PAR-20-255)
  National Human Genome Research Institute
  National Cancer Institute
  National Eye Institute
  National Institute on Aging
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): New Application Due Dates: October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03) Clinical Trial Optional)
  (PAR-20-257)
  National Human Genome Research Institute
  John E. Fogarty International Center
  National Cancer Institute
  National Institute on Aging
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): New Application Due Dates: October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
  (PAR-20-279)
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): December 15, 2020; August 10, 2021; December 14, 2021; August 10, 2022; December 14, 2022; August 10, 2023
  
  

• NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
  (PAR-20-285)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): New Applications: October 14, 2020; February 18, 2021; June 18, 2021; October 14, 2021; February 22, 2022; June 20, 2022; October 18, 2022; February 14, 2023, June 14, 2023 by 5:00 PM local time of applicant organization. Resubmission or Revision Applications: November 18, 2020; March 22, 2021; July 14, 2021; November 18, 2021, March 22, 2022; July 20, 2022; November 18, 2022; March 14, 2023, July 23, 2023 by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Transition to Aging Research for Predoctoral Students (F99/K00)
  (RFA-AG-21-022)
  National Institute on Aging
  Application Receipt Date(s): October 22, 2020
  
  

• Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional)
  (RFA-AG-21-029)
  National Institute on Aging
  Application Receipt Date(s): November 10, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional)
  (RFA-AR-21-008)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): October 19, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date..
  
  

• NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
  (RFA-DK-20-024)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): January 06, 2021
  
  

• Limited Competition: Data Coordinating Center (DCC) for Completion of Ongoing MFMU Network Protocols (U24 Clinical Trial Optional)
  (RFA-HD-21-028)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): September 4, 2020
  
  

• Limited Competition: Clinical Centers for Completion of Ongoing MFMU Network Protocols (UG1 Clinical Trial Optional)
  (RFA-HD-21-029)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): September 4, 2020
  
  

• Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01, Clinical Trial Optional)
  (RFA-HG-20-048)
  National Human Genome Research Institute
  National Cancer Institute
  Application Receipt Date(s): October 28, 2020 and July 8, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Investigator-Initiated Research on Genetic Counseling Processes and Practices (R21, Clinical Trial Optional)
  (RFA-HG-20-049)
  National Human Genome Research Institute
  Application Receipt Date(s): October 28, 2020 and July 8, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• The NINDS Human Biospecimen and Data Repository (U24 Clinical Trial Not Allowed)
  (RFA-NS-20-031)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): October 20, 2020